Viking Therapeutics' VK2735 Shows Strong Weight Maintenance with Less Frequent Dosing
Event summary
- Viking Therapeutics reported 22% placebo-adjusted weight loss at week 33 with weekly dosing of VK2735 at 17.5 mg, with no plateau observed.
- Up to 97% of weight loss was maintained with every-other-week dosing, and up to 90% with monthly dosing.
- GI adverse event rates were similar to placebo during the maintenance phase.
- The study evaluated both subcutaneous and oral formulations of VK2735 for obesity treatment.
The big picture
Viking Therapeutics' positive results for VK2735 come at a time when the obesity treatment market is rapidly evolving, with increasing focus on long-term weight maintenance and patient adherence. The company's ability to demonstrate effective weight loss maintenance with less frequent dosing could differentiate VK2735 in a competitive landscape dominated by weekly and bi-weekly dosing regimens. The results also highlight the potential of dual GLP-1/GIP agonists in addressing metabolic disorders beyond just weight loss.
What we're watching
- Dosing Flexibility
- Whether the extended dosing regimens will improve patient adherence and long-term weight management.
- Oral Formulation
- The potential impact of exploring oral maintenance dosing regimens in future studies.
- Market Positioning
- How Viking Therapeutics will position VK2735 against existing GLP-1/GIP agonists like tirzepatide.